These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065 [TBL] [Abstract][Full Text] [Related]
6. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553 [TBL] [Abstract][Full Text] [Related]
7. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. Cain LE; Phillips A; Lodi S; Sabin C; Bansi L; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; de Wolf F; Bucher HC; Elzi L; Touloumi G; Vourli G; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Abgrall S; Costagliola D; Hernán MA; AIDS; 2012 Aug; 26(13):1691-705. PubMed ID: 22546987 [TBL] [Abstract][Full Text] [Related]
8. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918 [TBL] [Abstract][Full Text] [Related]
9. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort. Bock P; Fatti G; Grimwood A Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113 [TBL] [Abstract][Full Text] [Related]
10. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724 [TBL] [Abstract][Full Text] [Related]
11. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. Shearer K; Brennan AT; Maskew M; Long L; Berhanu R; Sanne I; Fox MP J Int AIDS Soc; 2014; 17(1):19065. PubMed ID: 25361827 [TBL] [Abstract][Full Text] [Related]
12. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886 [TBL] [Abstract][Full Text] [Related]
13. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163 [TBL] [Abstract][Full Text] [Related]
14. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261 [TBL] [Abstract][Full Text] [Related]
15. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036 [TBL] [Abstract][Full Text] [Related]
16. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061 [TBL] [Abstract][Full Text] [Related]
17. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. Abgrall S; Yeni PG; Bouchaud O; Costagliola D; Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091 [TBL] [Abstract][Full Text] [Related]
19. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. Abgrall S; Yeni PG; Bouchaud O; Costagliola D; AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356 [TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E; AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]